Why Attend
Join us at the International Phage Futures Congress in 2021, as we create a virtual stage upon which to initiate all-important discussions & forge partnerships between key stakeholders from all over the world. Experts in their respective fields will discuss how to translate new phage-based applications into clinical studies & beyond.
Discover how you can be at the forefront of the developing phage therapy market.
Network & learn from established biotech companies, emerging start-ups, leading academics, global accelerator representatives, investment firms, international healthcare organisations & regulatory bodies.
Among other topics, expect to hear & participate in:
- Advice on how to successfully navigate clinical trial progression to prove efficacy along with recent developments from leading biotechs in phage therapeutic trials targeting chronic & acute illnesses.
- Regulatory discussions between international governing bodies with region specific follow-up conversations with the experts.
- Insights into new fields for phage application, such as oncology, diagnostics & microbial gene therapy.
- Expert advice on how to find & secure financial investments.
Who Will Be There
Past attendees
TESTIMONIALS
POSTER SUBMISSIONS
Are you a young researcher looking to showcase your recent work to the phage community?
Our dedicated poster session is the perfect way to get your research noticed, ideal for PhD students or Post-Doctoral researchers. In order to present a ‘virtual’ poster at the forum you need to be registered as a delegate. Your presentation will be displayed on our content platform, available for any attending delegate to view on demand before, during or after the congress. We shall encourage delegates to view posters, identify their favourite submissions & contact authors via the integrated networking platform during the event! The top performing authors shall receive an exclusive invitation to participate as a panellist in a public webinar, chaired by an expert in the phage community, allowing you to showcase you work to a wider audience!
Poster abstract submission deadline is 6pm (EST) on Friday 22nd January 2021
Posters should be a one page PDF in portrait orientation.
Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!
If you have any questions please contact [email protected]
Early Confirmed Speakers
Dr Paul Turner
Dr Benjamin Chan
Dr Timothy Lu
Dr David Pride
Dr Gina Suh
Dr Richard Alm
Richard joined CARB-X as an Alliance Director following almost 20 years in large pharma Infection R&D teams followed by 4 years at a small antibacterial biotech company. He has supported the progression of small molecule compounds from discovery through to late-stage clinical development. He obtained his PhD in molecular microbiology from the University of Adelaide, and prior to joining industry he held two post-doctoral positions in the AMR area, one in Australia and one in Canada. Richard is also a consultant on the Global Action Plan on Antimicrobial Resistance for the World Health Organization (WHO).
Dr Todd Black
Dr Dave Ousterout
Dave Ousterout is a co-founder and Chief Scientific Officer for Locus Biosciences. Dave holds a PhD from Duke University where he developed novel gene editing approaches for correcting mutations that cause Duchenne muscular dystrophy. His expertise is in protein engineering and early stage applications of new technologies to treat human diseases. At Locus, Dave is responsible for development of Locus’s crPhage platform and early stage product development. Prior to Locus, Dave was a consultant at McKinsey & Company.
Dr Cara Fiore
Dr Joe Campbell
I am a program officer in the division of microbiology and infections diseases (DMID) in the National Institute of Allergies and Infectious Diseases (NIAID). My primary role is running the base contract under which our in vitro testing pre-clinical services are conducted (https://www.niaid.nih.gov/research/vitro-assessment-antimicrobial-activity-resources). In addition, I am involved in the running of contracts in our pre-clinical models of diseases base contract (https://www.niaid.nih.gov/research/pre-clinical-models-infectious-disease). Finally, I run DMID’s bacteriophage interest group. The goal of this group is to work with the FDA and other federal agencies to promote the clinical use of bacteriophages.
Michael Higgins
Dr Shawna McCallin
Dr Biswajit Biswas
Dr Henry Chambers
Dr Michael Koeris
Dr Mimi Yen
Dr Xavier Duportet
Dr Tobi Nagel
Photo Credit: Mark Warren
Phages for Global Health is a nonprofit organization that facilitates the application of phages to combat antimicrobial resistance in developing countries. We accomplish this mission in two general ways: by delivering laboratory training workshops through which we teach scientists in developing countries how to isolate and characterize phages locally; and by partnering with developing world researchers to co-develop phage products for specific applications in their countries. Before founding Phages for Global Health, Tobi had 15 years experience in the pharmaceutical industry where she worked with international teams to co-develop products that have been tested in over 80 clinical trials worldwide.
Dr Steven Theriault
Dr Frenk Smrekar
Dr Carrie-Lynn Langlais Furr
Dr Danish Malik
Dr Jon Iredell
Dr Nick Conley
Dr. Nick Conley is Principal Scientist for Locus Biosciences. Before joining Locus in 2018, Nick was co-founder of EpiBiome, a South San Francisco-based precision microbiome engineering company that built the world’s first fully automated high-throughput phage discovery, characterization, and genomics platform, where he served in various roles, including CEO and Chief Science Officer. During this time, the company gained admission into Illumina Accelerator, Johnson & Johnson Innovation’s JLABS, and Stanford-StartX; secured non-dilutive funding from the Bill & Melinda Gates Foundation and the US Department of Defense; established a top-3 pharma partnership; and raised more than $10 million dollars in financing. Prior to EpiBiome, Nick was Staff Scientist at HGST, a Western Digital Company. Nick completed a postdoc in Developmental Biology at Stanford University, and he holds a PhD and BS in Chemistry from Stanford University and The University of Texas at Austin, respectively.
Anupama Hoey
Dr Sailaja Puttagunta
Professor Martha Clokie
Martha Clokie is Professor of Microbiology at the University of Leicester where she leads a group of post-doctoral researchers and PhD students working on different aspects of therapeutic development of phages that target human and animal pathogens. Her work encompasses all aspects of phage therapy development – from unravelling fundamental biology to product development, and commercialisation. She is currently developing phages for major gut pathogens including Clostridial and Salmonella species, for respiratory pathogens and for antibiotic resistant bacteria that cause UTIs. She is also developing a phage based diagnostic test for Borrelia. Three patents have been filed from her work.
Dr Graham Hatfull
Dr Bob Blasdel
Dr Barbara Hubad
Greg Merril
Dr Subhendu Basu
Professor Martha Clokie
Martha Clokie is Professor of Microbiology at the University of Leicester where she leads a group of post-doctoral researchers and PhD students working on different aspects of therapeutic development of phages that target human and animal pathogens. Her work encompasses all aspects of phage therapy development – from unravelling fundamental biology to product development, and commercialisation. She is currently developing phages for major gut pathogens including Clostridial and Salmonella species, for respiratory pathogens and for antibiotic resistant bacteria that cause UTIs. She is also developing a phage based diagnostic test for Borrelia. Three patents have been filed from her work.
Ella Balasa
Tell me about… your business
I am a patient advocate, a scientist, a freelance writer, and a person living with cystic fibrosis. Over the past few years, I have become involved in the CF community through serving on research committees, organizing CF virtual events, serving as a director for the US Adult CF Association, and speaking at both local and national levels to raise awareness for CF and shed light to the increasing problem of antibiotic resistance to the CF population. Having a degree in biology, I have worked in an environmental microbiology lab and I've dedicated my work to studying antibiotic resistant organisms and genes from an environmental perspective in surface waters affected by anthropogenic sources. As a patient, I find fascinating the connection between the bacteria that live in the lungs of those affected by CF and the way these same organisms thrive in the environment.
Along with an interest in science, I have developed an interest for writing. I have been able to provide a scientific voice and encourage empowerment to the CF community by occasionally writing about my research experiences as well as introspectively writing about the increasing hardship yet countless triumphs that come along with living a life with a chronic disease.
Dr Adam Ostrowski
Adam is a molecular microbiologist and an applications specialist at Cellexus International Ltd, where he helps customers find the optimal combination of bioreactor solutions offered by Cellexus and achieve the best possible results using our technology. Adam also helps develop new applications and technical solutions for our airlift-mixed single-use bioreactor range and delivers custom requests and improvements requested by our customers. Before joining Cellexus, Adam worked in bacteriophage treatment development for plant crop protection and during his academic career has studied Type VI Secretion system and functional proteins in bacterial communities.
Dr Peter Beyer
Peter Beyer, a trained lawyer, is a Senior Advisor with the World Health Organization (WHO) in Geneva where he leads a team working on global initiatives on antimicrobial resistance. He focuses on developing global instruments to combat antimicrobial resistance and to foster the development of new antimicrobial treatments. Peter was instrumental in setting up the Global Antibiotic R&D Partnership (GARDP), a foundation that is developing new antibacterial treatments as well as the trilateral collaboration among the World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and WHO. Previously, Peter Beyer was a Legal Advisor to the Swiss Federal Institute of Intellectual Property in Berne. He negotiated bilateral free trade agreements for the European Free Trade Association (EFTA) and was responsible for the bilateral dialogue between Switzerland and China on intellectual property. Prior to joining the Swiss civil service, Peter Beyer worked with the Ecologic Institute in Berlin on environmental law and policy.
Josh Hayes
Lorenzo Corsini
Lorenzo is co-founder and co-CEO of PhagoMed, a biotech company developing targeted antimicrobials to treat microbiome-related conditions based on endolysins. From 2008 to 2017, he worked for the Boston Consulting Group. In his latest function as a Principal, he was advising pharmaceutical companies on topics ranging from corporate strategy to efficiency and quality in manufacturing, and leading large teams of consultants across multiple projects. Before, he did his PhD in molecular biology at EMBL Heidelberg. Lorenzo has diploma degrees in biochemistry and business administration.
Partners
GMP Partner
JAFRAL
Website: https://jafral.com/
JAFARAL is world’s leading CMO for production of bacteriophages, because it’s has more than 10 years’ experience in manufacturing of phages, other biologics production, large scale production and knowing GMP guidelines. Likewise, JAFRAL has all these years also been involved in plasmid DNA and recombinant proteins production at various levels. JAFRAL’s custom development and manufacturing services have helped developers across the globe to accelerate research and open up their laboratories for ground-breaking science and breakthrough discoveries.
Silver Event Partner
Cellexus
Website: http://www.cellexus.com/
Cellexus was established in 2008, to develop a scalable single use bioreactor (SUB) for industrial and academic scientists to grow cell cultures in their laboratories, rapidly and in a controlled environment, for use in a wide range of applications including life sciences, brewing, biopharmaceutical and agricultural feed.
Mary Ann Liebert
Website: https://home.liebertpub.com/publications/phage/652
Please visit our website for more information.Lead Media Partner
Phage Directory
Phage Directory promotes and accelerates the safe and effective use of phages in medicine, agriculture, and biotechnology around the world. We provide insight and support to communities and organizations interested in understanding and using phages.
Phage Directory can support you to:
- Stay up-to-date on new developments in phage research and phage therapy
- Understand the regulatory, scientific and tech landscape around phages and phage therapy
- Find and recruit individuals with phage expertise
- Develop phage-based technologies and products
- Organize phage and phage therapy-related conferences, seminars and workshops
Media Partner
Bacteriophage.news
Website: https://www.bacteriophage.news/
Please visit our website for more information.Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Platform Preview
The Agenda
Fill in your details to download a copy of the 2021 Phage Futures Congress agenda to see the topics being covered and why you should attend.
Agenda launched!
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.